Causes of mortality in COPD;Causas de mortalidad en la EPOC

Archivos de Bronconeumologia

Volumn 45, Issue SUPPL.5, 2009, Pages 8-13

  Soriano Ortiz, Joan B ^a,b   Almagro, Pere ^c   Roig, Jaume Sauleda ^b,d  

^a Laboratory of Microbial Pathogenesis   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Comorbidities; COPD; General population; Mortality

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH CERTIFICATE; HUMAN; LUNG CANCER; MORTALITY; PRACTICE GUIDELINE; RESPIRATORY FAILURE; RISK FACTOR; SMOKING; SPAIN;

CAUSE OF DEATH; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 72149110395     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(09)72857-1     Document Type: Article

References (50)

1. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
2. Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27 (2006) 397-412
3. Disponible en: http://www.inebase.es
4. WHO Atlas of smoking worldwide; 2003.
5. Woloshin S., Schwartz L.M., and Welch H.G. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst 100 (2008) 845-853
6. Pride N.B., and Soriano J.B. Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity, and smoking. Curr Opin Pulm Med 8 (2002) 95-101
7. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., and Connett J.E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
8. Chapman K.R., Mannino D.M., Soriano J.B., Vermeire P.A., Buist A.S., Thun M.J., et al. The Global Burden of COPD: Epidemiology and costs of COPD. Eur Respir J 27 (2006) 188-207
9. Sobradillo-Peña V., Miravitlles M., Jiménez M.A., Gabriel R., Viejo J.L., Fernando J., et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch Bronconeumol 35 (1999) 159-166
10. Sobradillo-Peña V., Miravitlles M., Gabriel R., Jimenez-Ruiz C.A., Villasante C., Masa J.F., et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 118 (2000) 981-989
11. Izquierdo J.L. The burden of COPD in Spain: Results from the Confronting COPD Survey. Respiratory Medicine 97 (2003) s61-s67
12. Banegas J.R., Diez Gañán L., González Enriquez J., Villar Álvarez F., and Rodríguez Artalejo. La mortalidad atribuible al tabaquismo comienza a descender en España. Med Clin (Barc) 124 (2005) 769-771
13. Masa J.F., Sobradillo V., Villasante C., Jiménez-Ruiz C.A., Fernández-Fau L., Viejo J.L., et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol 40 (2004) 72-79
14. Izquierdo J.L., and De Miguel J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. J COPD 1 (2004) 215-223
15. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
16. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía practica para el diagnostico y el tratamiento de la enfermedad pulmonar obstructiva crónica: guías conjuntas SEPAR-ALAT. Arch Bronconeumol 44 (2008) 271-281
17. Zielinski J., MacNee W., Wedzicha J., Ambrosino N., Braghiroli A., Dolensky J., et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 52 (1997) 43-47
18. Soriano J.B., Maier W.C., Egger P., Visick G., Thakrar B., Sykes J., et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 55 (2000) 789-794
19. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Mendez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012
20. Soler Cataluña J.J., and Martínez García M.A. Factores pronóstico en la EPOC. Arch Bronconeumol 43 (2007) 680-691
21. Rodríguez-Roisin R., and Soriano J.B. Chronic Obstructive Pulmonary Disease with Lung Cancer and/or Cardiovascular Disease. Proc Am Thorac Soc 5 (2008) 842-847
22. Mannino D.M., Browmn C., and Giovino G.A. Obstructive lung disease deaths in the United States from 1979 through 1993. Am J Respir Crit Care Med 156 (1997) 814-818
23. Hansell A.L., Walk J.A., and Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 22 (2003) 809-814
24. Smyth E.T., Wright S.C., Evans A.E., Sinnamon D.G., and MacMahon J. Death from airways obstruction: accuracy of certification in Northern Ireland. Thorax 51 (1996) 293-297
25. May K.L. Death certificates in asthma and COPD patients (survey of statistical data in Warsaw). Monaldi Arch Chest Dis 57 (2002) 253-257
26. Vilkman S., Keistinen T., Tuuponen T., and Kivela S.L. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 64 (1997) 281-284
27. Moser K.M., Shibel E.M., and Beamon A.J. Acute respiratory failure in obstructive lung disease. Long-term survival after treatment in an intensive care unit. JAMA 225 (1973) 705-707
28. Render M.L., Weinstein A.S., and Blaustein A.S. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest 107 (1995) 162-168
29. Abroug F., Ouanes-Besbes L., Nciri N., Sellami N., Addad F., Hamda K.B., et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 174 (2006) 990-996
30. Berger J.S., Sanborn T.A., Sherman W., and Brown D.L. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 94 (2004) 649-651
31. Holguin F., Folch E., Redd S.C., and Mannino D.M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128 (2005) 2005-2011
32. Soriano J.B., Visick G.T., Muellerova H., Payvandi N., and Hansell A.L. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128 (2005) 2099-2107
33. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
34. Mannino D.M., Thorn D., Swensen A., and Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32 (2008) 962-969
35. Garcia-Aymerich J., Barreiro E., Farrero E., Marrades R.M., Morera J., and Antó J.M. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 16 (2000) 1037-1042
36. Almagro P., Calbo E., Ochoa de Echagüen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 121 (2002) 1441-1448
37. McGarvey L.P., John M., Anderson J.A., Zvarich M., Wise R.A., and TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 62 (2007) 411-415
38. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al., UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
39. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
40. Keistinen T., Tuuponen T., and Kivelä S.L. Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. Respir Med 92 (1998) 568-572
41. Editorial. The burden of disease. BMJ 325 (2002) 925-928
42. Soriano J.B., and Sauleda J. How the COPD patient should be assessed for comorbidities. In: Rennard S.I., Rodríguez-Roisin R., Huchon G., and Roche N. (Eds). Clinical management of chronic obstructive pulmonary disease. 2nd ed. (2007), Informa healthcare, New York 211-238
43. Löfdahl C.G., Postma D.S., Pride N.B., Boe J., and Thorén A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 29 (2007) 1115-1119
44. Kiri V.A., Fabbri L.M., Davis K.J., and Soriano J.B. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med 103 (2009) 85-90
45. Garcia-Aymerich J., Gómez F.P., Antó J.M., and On behalf of the PAC-COPD Research Study Group. Phenotype characterisation and course of chronic obstructive pulmonary disease (COPD) in the PAC-COPD Study: design and methods. Arch Bronconeumol 45 (2009) 4-11
46. Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L., et al., ECLIPSE investigators. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31 (2008) 869-873
47. San Román-Terán C.M., Guijarro-Merino R., Gómez Huelgas R., Montero-Ribas L., and Pérez M. Epidemiología hospitalaria de la EPOC en España. Rev Clin Esp 207 Supl 1 (2007) 3-7
48. Jensen H.H., Godtfredsen N.S., Lange P., and Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 28 (2006) 781-785
49. Goldacre M.J. Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health 47 (1993) 491-496
50. Fabbri L.M., Luppi F., Beghé B., and Rabe K.F. Complex chronic comorbidities of COPD. Eur Respir J 31 (2008) 204-212